Clinical outcomes of first line FOLFIRINOX vs. gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer at the Yale Smilow Hospital System

Timil Patel, Joseph Miccio, Michael Cecchini, Thejal Srikumar, Stacey Stein, Jeremy Kortmanksy, Kimberly Johung, Jill Lacy